Date:2/26/2009

NASDAQ Capital Market and the transfer was effective as of November 14, 2008. The Company then received a Deficiency Letter dated December 1, 2008, from the NASDAQ Staff stating that, for 10 consecutive trading days, the market value of the Company's listed securities had been below the minimum $35,000,000 requirement for continued inclusion on the NASDAQ Capital Market. The Company then formally initiated the steps to voluntarily delist by notifying the NASDAQ Stock Market and issuing a press release regarding its intention to voluntarily delist its common stock from the NASDAQ Capital Market. The Company received the consent of the holders of over a majority in value of the Company's $42,085,000 aggregate principal amount of 6% convertible senior notes issued in November 2006 and amended the trust indenture governing these notes, so as to permit delisting from NASDAQ. See below in the current Liquidity and Capital Resources section for discussion of the impact of the delisting on the equity line of credit facility with Cityplatz Limited. The Company's listing on the Toronto Stock Exchange was not affected by the delisting from NASDAQ. The Company currently expects to continue to be subject to the filing and other obligations of the US securities laws applicable to non-US reporting companies during 2009.

On July 17, 2008, the Company acquired 100% of the remaining outstanding capital stock that it did not already own of Innodia Inc. (Innodia), a private company engaged in developing compounds for the treatment of diabetes, obesity and related metabolic conditions and diseases. Prior to the acquisition, the Company indirectly held 23% of Innodia's capital stock. The Company acquired all of the operations of Innodia including the intellectual property assets related to its diabetes and obesity projects. As a result of the transaction, the Company regained exclusive rights to its diabetes platform and all related compounds. The purchase price, in the amount o
'/>"/>

SOURCE BELLUS HEALTH INC. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Related medicine news :

1. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
2. BELLUS HEALTH reports results for first quarter of fiscal 2008
3. BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
4. BELLUS Health announces closing of Innodia acquisition
5. BELLUS Health provides update on activities
6. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
7. BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
8. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
9. BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
10. BELLUS Health announces formal notice to voluntarily delist from NASDAQ
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BELLUS Health Inc.